Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

CoTherix Files Ventavis NDA In Pulmonary Arterial Hypertension

July 2, 2004

CoTherix Files Ventavis NDA In Pulmonary Arterial Hypertension

July 2, 2004

Cellegy Resubmits NDA For Cellegesic In Anal Fissures

July 1, 2004

Amylin, Lilly File For Approval Of Exenatide In Type II Diabetes

July 1, 2004

Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. filed a new drug application seeking approval of exenatide as a treatment for Type II diabetes. (BioWorld Today)

Amylin, Lilly File For Approval Of Exenatide In Type II Diabetes

July 1, 2004

Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. filed a new drug application seeking approval of exenatide as a treatment for Type II diabetes. (BioWorld Today)

Cellegy Resubmits NDA For Cellegesic In Anal Fissures

July 1, 2004

Decisions Regarding Follow-On Biologics To Be Made In Public

June 30, 2004

Decisions Regarding Follow-On Biologics To Be Made In Public

June 30, 2004

LSBC, University Of Louisville Join Up To Develop HPV Drugs

June 29, 2004

LSBC, University Of Louisville Join Up To Develop HPV Drugs

June 29, 2004

View All Articles by Kim Coghill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.